[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Genoss Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,67,90,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100634410","clinical-impact-of-dcb-based-versus-des-based-intervention-in-patients-with-mvcad-100634410",false,"NCT07539324","Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD","Clinical Impact of Drug-Coated-Balloon-based Versus Drug-Eluting-Stent-based Intervention in Patients With Multivessel Coronary Artery Disease : A Prospective, Multicenter, Active-controlled, Randomized, Single-blind, Investigator-initiated Clinical Trial","DCBMultivessel","Inclusion Criteria:\n\n1. Male or female adults aged 20 years or older with stable angina, silent myocardial ischemia, unstable angina, or non-ST-segment elevation myocardial infarction (NSTEMI).\n2. In cases of ST-segment elevation myocardial infarction (STEMI), patients who have undergone successful primary percutaneous coronary intervention (PCI) without complications, at least 48 hours post-procedure, and whose target lesion(s) show no evidence of thrombus.\n3. Patients with multivessel coronary artery disease, defined as angiographic stenosis of 50% in at least two major epicardial coronary arteries requiring PCI as determined by the investigator.\n4. Reference vessel diameter (RVD) of the target lesion(s) between 2.25 mm and 4.0 mm by visual estimation or quantitative coronary angiography (QCA).\n5. Target lesions suitable for treatment with either drug-eluting stents (DES) or drug-coated balloons (DCB).\n6. Patients who have voluntarily provided written informed consent and are willing and able to comply with all protocol-specified requirements.\n\nExclusion Criteria:\n\n1. Cardiogenic shock or patients requiring mechanical or pharmacological circulatory support.\n2. Patients with a life expectancy of less than 2 years due to comorbid conditions.\n3. Patients who are currently participating or planning to participate in other interventional clinical trials, excluding observational studies.\n4. Women who are pregnant or have childbearing potential.\n5. Patients with a known hypersensitivity or allergy to contrast media, L-605 Cobalt-Chromium (Co-Cr) alloy, PLA and PLGA polymers, shellac, Vitamin E-TPGS, paclitaxel, or sirolimus.\n6. Patients with a target lesion located within a saphenous vein graft (SVG) or an arterial graft.\n7. Patients with target vessels\u002Flesions that are excessively tortuous, angulated, or severely calcified, such that pre-dilatation cannot be performed or has failed, making the application of the investigational medical device difficult.","ALL","20 Years",{"count":20,"type":21},892,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.",[27,28],"Multi Vessel Coronary Artery Disease","Percutaneous Coronary Intervention","NOT_YET_RECRUITING","2026-04-13",{"date":32,"type":33},"2026-04-20","ACTUAL",{"date":35,"type":21},"2026-04-15",{"date":37,"type":21},"2032-07-31",{"name":39,"class":40},"Genoss Co., Ltd.","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100625633","safety-and-effectiveness-of-genoss-pcb-in-patients-with-long-femoropopliteal-lesion-100625633","NCT07425171","Safety and Effectiveness of GENOSS PCB in Patients With Long Femoropopliteal Lesion","Safety and Effectiveness of GENOSS PCB (Paclitaxel-coated Balloon) in Patients With Long Femoropopliteal Lesion: A Prospective, Multicenter, Observational Study (GENOSS-PCB Long)","\\\u003CInclusion criteria\\>\n\nEnrollment in the study was limited to patients who met the following inclusion criteria:\n\n1. Subject was ≥19 years of age.\n2. Subject had target limb Rutherford classification 2, 3, 4 or 5.\n3. Subjects with a stenosis of 70% or greater in the femoropopliteal artery.\n4. Subjects with a stenotic or occlusive lesion measuring ≥150 mm in total length. (Multiple adjacent lesions separated by less than 3 cm from angiographically healthy segments are treated as a single lesion.)\n5. Subjects with a reference vessel diameter of ≥4 mm but ≤7 mm.\n6. Subject provided written informed consent and was willing to comply with the study follow-up requirements.\n\n\\\u003CExclusion criteria\\>\n\nPatients were not permitted to enroll in the study if they met any of the following exclusion criteria:\n\n1. Subjects was allergic to paclitaxel.\n2. Subjects with contraindications or hypersensitivity to antiplatelet therapy.\n3. Subject had life expectancy of less than 2 years.\n4. Those who have undergone vascular surgery on the target lesion within the past 6 weeks.\n5. Those who have in-stent restenosis (ISR) on the target lesion.\n6. Those who have non-arteriosclerotic vascular disease, such as an aneurysm or vasculitis, on the target lesion.\n7. Women who were pregnant, breast-feeding or intended to become pregnant.\n8. Those who cannot perform pre-dilatation or who fail to apply the device, making it difficult to apply the device.\n9. Those who have a Grade D or higher vascular dissection restricting blood flow after pre-dilatation or who require stent placement.\n10. Those who, in the investigator's judgment, are not suitable for this study or may increase the risks associated with participation in the study.","19 Years","85 Years",{"count":51,"type":21},300,"OBSERVATIONAL","The purpose of this study is to evaluate the long-term safety and efficacy of GENOSS PCB in patients with long femoropopliteal lesions who underwent percutaneous transluminal angioplasty using GENOSS PCB.",[55,56,57],"PTA (Percutaneous Transluminal Angioplasty)","Femoropopliteal Artery Disease","Long Femoropopliteal Artery Disease","2026-02-13",{"date":60,"type":33},"2026-02-20",{"date":62,"type":21},"2026-02-24",{"date":64,"type":21},"2028-12-31",{"name":39,"class":40},1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":52,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":66},"100521886","efficacy-and-safety-of-short-duration-of-dapt-after-genoss-des-implantation-in-patients-with-coronary-artery-disease-100521886","NCT06075420","Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease","A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease","DAPTShort","Inclusion Criteria:\n\n1. Patients of 19 and over\n2. Patients with coronary artery disease treated with GENOSS SES\n3. Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants\n\nExclusion Criteria:\n\n1. Patients with cardiogenic shock at the time of hospitalization\n2. Patients who are pregnant or planning to become pregnant\n3. Patients with a life expectancy of less than 1 year\n4. Patients participating in randomized controlled trials using other medical devices\n5. Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)",{"count":76,"type":21},1000,"12 Months","The objective of study is to evaluate the efficacy and safety of short duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease.",[28,80],"Dual Antiplatelet Therapy","RECRUITING","2025-02-18",{"date":84,"type":33},"2025-02-21",{"date":86,"type":33},"2021-08-18",{"date":88,"type":21},"2027-12-31",{"name":39,"class":40},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":97,"targetDuration":77,"studyType":52,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":105,"locationsCount":66},"100521887","efficacy-and-safety-of-1-year-duration-of-dapt-after-genoss-des-implantation-in-patients-with-coronary-artery-disease-according-to-the-complex-higher-risk-procedure-100521887","NCT06075433","Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure","A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of 1 Year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-Risk Procedure","DAPTLong",{"count":76,"type":21},"The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.",[100,28,80],"Coronary Artery Disease",{"date":84,"type":33},{"date":103,"type":33},"2022-05-13",{"date":88,"type":21},{"name":39,"class":40},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":113,"targetDuration":77,"studyType":52,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":66},"100521196","efficacy-of-osfit-drug-eluting-stent-in-coronary-ostial-artery-stenosis-100521196","NCT06066450","Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis","Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis: Multi-center, Prospective, Observational Study (OSFIT Registry)","Inclusion Criteria:\n\n1. Age 19 and above.\n2. Patients who have voluntarily decided to participate in this study and have provided written consent in accordance with the subject's agreement.\n3. Patients who have undergone percutaneous coronary intervention for stenosis within 5mm of the ostium of the coronary artery using OSFITTM drug-eluting stents. (In case of simultaneous stent placement for other lesions, only GenossTM drug-eluting stents should be used.)\n\nExclusion Criteria:\n\n1. Patients with contraindications to stent treatment and antiplatelet therapy or who have hypersensitivity.\n2. Patients with a life expectancy of less than 1 year.\n3. Pregnant or lactating women, or those wishing to become pregnant.\n4. Patients with ST-elevation myocardial infarction (STEMI).",{"count":76,"type":21},"The purpose of this observational study is to evaluate the long-term effectiveness and safety of the OSFIT drug-eluting stent designed to facilitate procedures in coronary artery lesions. Additionally, the study aims to verify the accuracy of stent placement in the lesion of interest using Optical Coherence Tomography (OCT) among subgroups of participants.\n\nThe primary endpoint was defined as the composite of target lesion failure (TLF) at the 12-month mark, including cardiac death, target vessel myocardial infarction (MI), or target lesion revascularization.",[116,100],"Drug-eluting Stent","2023-10-30",{"date":119,"type":33},"2023-11-01",{"date":121,"type":33},"2023-07-07",{"date":123,"type":21},"2026-12-31",{"name":39,"class":40},""]